Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, monoclonal antibodies (mAbs) to treat serious medical conditions with a primary clinical focus on severe respiratory diseases and cancer, announced today its corporate highlights and financial results for the second quarter ended June 30, 2013.
Hey, check out all the research scientist jobs. Post your resume today!
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, monoclonal antibodies (mAbs) to treat serious medical conditions with a primary clinical focus on severe respiratory diseases and cancer, announced today its corporate highlights and financial results for the second quarter ended June 30, 2013.
Hey, check out all the research scientist jobs. Post your resume today!
